Fingolimod (BioDeep_00000271826)

   

natural product


代谢物信息卡片


Fingolimod

化学式: C19H33NO2 (307.25111580000004)
中文名称: 芬戈莫德
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
InChI: InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

描述信息

L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators
COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials
C308 - Immunotherapeutic Agent
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

1 个代谢物同义名

Fingolimod



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

9 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Daniela M Magalhães, Nicolas A Stewart, Myrthe Mampay, Sara O Rolle, Chloe M Hall, Emad Moeendarbary, Melanie S Flint, Ana M Sebastião, Cláudia A Valente, Marcus K Dymond, Graham K Sheridan. The sphingosine 1-phosphate analogue, FTY720, modulates the lipidomic signature of the mouse hippocampus. Journal of neurochemistry. 2024 Jun; 168(6):1113-1142. doi: 10.1111/jnc.16073. [PMID: 38339785]
  • Nizameddin Koca, Meral Seferoğlu. Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis. Multiple sclerosis and related disorders. 2023 Sep; 77(?):104876. doi: 10.1016/j.msard.2023.104876. [PMID: 37423049]
  • Jing Yang, Xin Guan, Simeng He, Lixiu Ge, Qiaoying Gao, Xiaoyang Wu. FTY720 attenuates acute colitis via colonic T cells reduction and inhibition of M1 macrophages polarization independent of CCR2-mediated monocytes input. International immunopharmacology. 2023 Aug; 123(?):110731. doi: 10.1016/j.intimp.2023.110731. [PMID: 37541109]
  • Tina Sepasi, Tahereh Ghadiri, Abbas Ebrahimi-Kalan, Farhad Bani, Mehdi Talebi, Reza Rahbarghazi, Sina Khodakarimi, Hanieh Beyrampour-Basmenj, Khaled Seidi, Soheil Abbaspour-Ravasjani, Mohammad-Reza Sadeghi, Amir Zarebkohan, Huile Gao. CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice. International journal of pharmaceutics. 2023 Apr; 636(?):122815. doi: 10.1016/j.ijpharm.2023.122815. [PMID: 36907279]
  • Gerhild van Echten-Deckert. The role of sphingosine 1-phosphate metabolism in brain health and disease. Pharmacology & therapeutics. 2023 Apr; 244(?):108381. doi: 10.1016/j.pharmthera.2023.108381. [PMID: 36907249]
  • Thomas Hach, Kasra Shakeri-Nejad, Marc Bigaud, Frank Dahlke, Massimiliano de Micco, Olivier Petricoul, Gordon Graham, Daniela Piani-Meier, Renato Turrini, Volker Brinkmann, Ferdinando Nicoletti. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2022 Nov; ?(?):. doi: 10.1089/jir.2022.0078. [PMID: 36454249]
  • Koki Tachibana, Kohshi Kusumoto, Mai Ogawa, Hidenori Ando, Taro Shimizu, Yu Ishima, Tatsuhiro Ishida, Keiichiro Okuhira. FTY720 Reduces Lipid Accumulation by Upregulating ABCA1 through Liver X Receptor and Sphingosine Kinase 2 Signaling in Macrophages. International journal of molecular sciences. 2022 Nov; 23(23):. doi: 10.3390/ijms232314617. [PMID: 36498944]
  • Priyanka Baloni, Matthias Arnold, Luna Buitrago, Kwangsik Nho, Herman Moreno, Kevin Huynh, Barbara Brauner, Gregory Louie, Alexandra Kueider-Paisley, Karsten Suhre, Andrew J Saykin, Kim Ekroos, Peter J Meikle, Leroy Hood, Nathan D Price, P Murali Doraiswamy, Cory C Funk, A Iván Hernández, Gabi Kastenmüller, Rebecca Baillie, Xianlin Han, Rima Kaddurah-Daouk. Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. Communications biology. 2022 10; 5(1):1074. doi: 10.1038/s42003-022-04011-6. [PMID: 36209301]
  • Dolores Camacho-Muñoz, Jennifer Niven, Salih Kucuk, Danilo Cucchi, Michelangelo Certo, Simon W Jones, Deborah P Fischer, Claudio Mauro, Anna Nicolaou. Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regulatory T cell responses through averting ceramide-mediated pathways. Biochemical pharmacology. 2022 Oct; 204(?):115211. doi: 10.1016/j.bcp.2022.115211. [PMID: 35985403]
  • Maria Pia Giannoccaro, Veria Vacchiano, Marta Leone, Federico Camilli, Corrado Zenesini, Ivan Panzera, Alice Balboni, Maria Tappatà, Annamaria Borghi, Fabrizio Salvi, Alessandra Lugaresi, Rita Rinaldi, Giulia Di Felice, Vittorio Lodi, Tiziana Lazzarotto, Rocco Liguori. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. Journal of neurology. 2022 Aug; 269(8):4000-4012. doi: 10.1007/s00415-022-11142-7. [PMID: 35503375]
  • Simone M Crivelli, Qian Luo, Daan van Kruining, Caterina Giovagnoni, Marina Mané-Damas, Sandra den Hoedt, Dusan Berkes, Helga E De Vries, Monique T Mulder, Jochen Walter, Etienne Waelkens, Rita Derua, Johannes V Swinnen, Jonas Dehairs, Erwin P M Wijnands, Erhard Bieberich, Mario Losen, Pilar Martinez-Martinez. FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Aug; 152(?):113240. doi: 10.1016/j.biopha.2022.113240. [PMID: 35689862]
  • Ladan Dayani, Masoud Sadeghi Dinani, Mehdi Aliomrani, Hossein Hashempour, Jaleh Varshosaz, Azade Taheri. Immunomodulatory effects of cyclotides isolated from Viola odorata in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Multiple sclerosis and related disorders. 2022 Aug; 64(?):103958. doi: 10.1016/j.msard.2022.103958. [PMID: 35716476]
  • Renata Rank Miranda, Natália Noronha Ferreira, Edmarcia Elisa de Souza, Paula Maria Pincela Lins, Leonardo Miziara Barboza Ferreira, Arne Krüger, Valéria Maria de Oliveira Cardoso, Edison Luiz Durigon, Carsten Wrenger, Valtencir Zucolotto. Modulating Fingolimod (FTY720) Anti-SARS-CoV-2 Activity Using a PLGA-Based Drug Delivery System. ACS applied bio materials. 2022 Jul; 5(7):3371-3383. doi: 10.1021/acsabm.2c00349. [PMID: 35732506]
  • Virginia Palomares Cabeza, Laura Y L Kummer, Luuk Wieske, Ruth R Hagen, Mariel Duurland, Veronique A L Konijn, Koos P J van Dam, Eileen W Stalman, Carolien E van de Sandt, Laura Boekel, Niels J M Verstegen, Maurice Steenhuis, Theo Rispens, Sander W Tas, Gertjan Wolbink, Joep Killestein, Taco W Kuijpers, S Marieke van Ham, Filip Eftimov, Anja Ten Brinke, Zoé L E van Kempen. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. Neurology(R) neuroimmunology & neuroinflammation. 2022 07; 9(4):. doi: 10.1212/nxi.0000000000001178. [PMID: 35523569]
  • Gary Álvarez Bravo, René Robles Cedeño, Marc Puig Casadevall, Lluís Ramió-Torrentà. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Cells. 2022 06; 11(13):. doi: 10.3390/cells11132058. [PMID: 35805142]
  • Giovanna S Manzano, Dylan R Rice, Eric C Klawiter, Marcelo Matiello, Rebecca L Gillani, Shahamat S Tauhid, Rohit Bakshi, Farrah J Mateen. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. Multiple sclerosis (Houndmills, Basingstoke, England). 2022 06; 28(7):1146-1150. doi: 10.1177/13524585221092309. [PMID: 35475382]
  • Edouard Januel, Jérôme De Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, Julie Pique, Xavier Moisset, Caroline Bensa, Adil Maarouf, Jean Pelletier, Sandra Vukusic, Bertrand Audoin, Céline Louapre. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple sclerosis (Houndmills, Basingstoke, England). 2022 06; 28(7):1155-1159. doi: 10.1177/13524585211049737. [PMID: 34931885]
  • David Leppert, Harald Kropshofer, Dieter A Häring, Frank Dahlke, Ashwini Patil, Rolf Meinert, Davorka Tomic, Ludwig Kappos, Jens Kuhle. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology. 2022 05; 98(21):e2120-e2131. doi: 10.1212/wnl.0000000000200258. [PMID: 35379762]
  • Anat Achiron, Mathilda Mandel, Michael Gurevich, Sapir Dreyer-Alster, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Gil Harari, Shlomo Flechter, Rina Falb. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. Journal of neurology. 2022 May; 269(5):2286-2292. doi: 10.1007/s00415-022-11030-0. [PMID: 35235002]
  • Rocco Capuano, Alvino Bisecco, Miriana Conte, Giovanna Donnarumma, Manuela Altieri, Elena Grimaldi, Gianluigi Franci, Annalisa Chianese, Massimiliano Galdiero, Nicola Coppola, Gioacchino Tedeschi, Antonio Gallo. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Multiple sclerosis and related disorders. 2022 Apr; 60(?):103724. doi: 10.1016/j.msard.2022.103724. [PMID: 35272145]
  • Christine M Sorenson, Mitra Farnoodian, Shoujian Wang, Yong-Seok Song, Soesiawati R Darjatmoko, Arthur S Polans, Nader Sheibani. Fingolimod (FTY720), a Sphinogosine-1-Phosphate Receptor Agonist, Mitigates Choroidal Endothelial Proangiogenic Properties and Choroidal Neovascularization. Cells. 2022 03; 11(6):. doi: 10.3390/cells11060969. [PMID: 35326420]
  • Pietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, Damiano Paolicelli, Francesco Patti, Marco Capobianco, Vincenzo Brescia Morra, Patrizia Sola, Ilaria Pesci, Giacomo Lus, Giovanna De Luca, Alessandra Lugaresi, Paola Cavalla, Sara Montepietra, Giorgia Teresa Maniscalco, Franco Granella, Paolo Ragonese, Marika Vianello, Laura Brambilla, Rocco Totaro, Simona Toscano, Simona Malucchi, Maria Petracca, Lucia Moiola, Diana Ferraro, Vito Lepore, Paola Mosconi, Michela Ponzio, Gioacchino Tedeschi, Giancarlo Comi, Mario Alberto Battaglia, Massimo Filippi, Maria Pia Amato, Maria Trojano. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. Neurology(R) neuroimmunology & neuroinflammation. 2022 03; 9(2):. doi: 10.1212/nxi.0000000000001141. [PMID: 35046084]
  • Recai Türkoğlu, Nesrin Baliç, Tuğçe Kızılay, Ruziye Erol, Ece Akbayır, Vuslat Yılmaz, Erdem Tüzün. Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. Multiple sclerosis and related disorders. 2022 Feb; 58(?):103524. doi: 10.1016/j.msard.2022.103524. [PMID: 35033838]
  • Jordan Brown, Colleen Everett, Jose A Barragan, Javier Vargas-Medrano, Bharathi S Gadad, Frank Nichols, Jorge L Cervantes. Multiple Sclerosis-associated Bacterial Ligand 654. Archives of medical research. 2022 02; 53(2):157-162. doi: 10.1016/j.arcmed.2021.11.002. [PMID: 34895764]
  • Jitendra Shrestha, Maftuna Shamshiddinova, Yong-Moon Lee, Yoon Sin Oh, Dong Jae Baek, Eun-Young Park. SK1 Inhibitor RB005 Induces Apoptosis in Colorectal Cancer Cells through SK1 Inhibition Dependent and Independent Pathway. Current molecular pharmacology. 2022; 15(3):570-581. doi: 10.2174/1874467214666210811151324. [PMID: 34382511]
  • Emilio Portaccio, Mattia Fonderico, Bernhard Hemmer, Tobias Derfuss, Bruno Stankoff, Krzysztof Selmaj, Mar Tintorè, Maria Pia Amato. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple sclerosis (Houndmills, Basingstoke, England). 2022 01; 28(1):132-138. doi: 10.1177/13524585211005339. [PMID: 33764197]
  • Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro, Assunta Bianco, Mariagrazia Rossi, Alessandra Cicia, Antonio Cortese, Alessandro Cruciani, Valeria De Arcangelis, Laura De Giglio, Francesco Motolese, Biagio Sancetta, Massimiliano Mirabella, Vincenzo Di Lazzaro. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022 01; 19(1):325-333. doi: 10.1007/s13311-021-01165-9. [PMID: 34859382]
  • Guerrieri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. Journal of neurology. 2022 Jan; 269(1):39-43. doi: 10.1007/s00415-021-10663-x. [PMID: 34189719]
  • Lichun Wang, Eleftheria Letsiou, Huashan Wang, Patrick Belvitch, Lucille N Meliton, Mary E Brown, Mounica Bandela, Jiwang Chen, Joe G N Garcia, Steven M Dudek. MRSA-induced endothelial permeability and acute lung injury are attenuated by FTY720 S-phosphonate. American journal of physiology. Lung cellular and molecular physiology. 2022 01; 322(1):L149-L161. doi: 10.1152/ajplung.00100.2021. [PMID: 35015568]
  • Ron Milo, Elsebeth Staun-Ram, Dimitrios Karussis, Arnon Karni, Mark A Hellmann, Erez Bar-Haim, Ariel Miller. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in immunology. 2022; 13(?):868915. doi: 10.3389/fimmu.2022.868915. [PMID: 35432335]
  • Mayuko Ikarashi, Junko Tsuchida, Masayuki Nagahashi, Shiho Takeuchi, Kazuki Moro, Chie Toshikawa, Shun Abe, Hiroshi Ichikawa, Yoshifumi Shimada, Jun Sakata, Yu Koyama, Nobuaki Sato, Nitai C Hait, Yiwei Ling, Shujiro Okuda, Kazuaki Takabe, Toshifumi Wakai. Plasma Sphingosine-1-Phosphate Levels Are Associated with Progression of Estrogen Receptor-Positive Breast Cancer. International journal of molecular sciences. 2021 Dec; 22(24):. doi: 10.3390/ijms222413367. [PMID: 34948163]
  • Mario Orrico, Agostino Nozzolillo, Stefano Gelibter, Francesca Sangalli, Paolo Preziosa, Massimo Filippi, Lucia Moiola. Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. Journal of neurology. 2021 Nov; 268(11):3975-3979. doi: 10.1007/s00415-021-10556-z. [PMID: 33852086]
  • Marja Niiranen, Aleksi Kontkanen, Olli Jääskeläinen, Hanna-Mari Tertsunen, Tuomas Selander, Päivi Hartikainen, Nadine Huber, Eino Solje, Annakaisa Haapasalo, Tarja Kokkola, Tarja Lohioja, Sanna-Kaisa Herukka, Sakari Simula, Anne M Remes. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Multiple sclerosis and related disorders. 2021 Nov; 56(?):103280. doi: 10.1016/j.msard.2021.103280. [PMID: 34627002]
  • Muhammad Asif, Mohammad Saleem, Hafiza Sidra Yaseen, Ashwaq Hs Yehya, Malik Saadullah, Hafiz Muhammad Zubair, Chern E Oon, Pegah Moradi Khaniabadi, Syed Haroon Khalid, Ikram Ullah Khan, Mahrukh. Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection. Future microbiology. 2021 11; 16(?):1289-1301. doi: 10.2217/fmb-2021-0024. [PMID: 34689597]
  • Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J Ward, Joseph Berger. COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series. Neurology(R) neuroimmunology & neuroinflammation. 2021 11; 9(1):. doi: 10.1212/nxi.0000000000001092. [PMID: 34848501]
  • Fredrik Sandesjö, Evangeline Wassmer, Kumaran Deiva, Maria Pia Amato, Tanuja Chitnis, Cheryl Hemingway, Lauren Krupp, Daniela Pohl, Kevin Rostasy, Emanuelle Waubant, Brenda Banwell, Ronny Wickström. Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic. Multiple sclerosis and related disorders. 2021 Nov; 56(?):103277. doi: 10.1016/j.msard.2021.103277. [PMID: 34624643]
  • Lanqiu Zhang, Hejun Gao, Lei Yang, Tianyu Liu, Qi Zhang, Jing Xun, Caixia Li, Lihua Cui, Ximo Wang. FTY720 induces neutrophil extracellular traps via a NADPH oxidase-independent pathway. Archives of biochemistry and biophysics. 2021 10; 711(?):109015. doi: 10.1016/j.abb.2021.109015. [PMID: 34437865]
  • Brian Corbett, Sandra Luz, Nathaniel Sotuyo, Jiah Pearson-Leary, Ganesh S Moorthy, Athena F Zuppa, Seema Bhatnagar. FTY720 (Fingolimod), a modulator of sphingosine-1-phosphate receptors, increases baseline hypothalamic-pituitary adrenal axis activity and alters behaviors relevant to affect and anxiety. Physiology & behavior. 2021 10; 240(?):113556. doi: 10.1016/j.physbeh.2021.113556. [PMID: 34390688]
  • Maria Pia Sormani, Matilde Inglese, Irene Schiavetti, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Giorgio Da Rin, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari, Germana Perego, Giampaolo Brichetto, Paola Gazzola, Antonio Mannironi, Maria Laura Stromillo, Cinzia Cordioli, Doriana Landi, Marinella Clerico, Elisabetta Signoriello, Jessica Frau, Maria Teresa Ferrò, Alessia Di Sapio, Livia Pasquali, Monica Ulivelli, Fabiana Marinelli, Graziella Callari, Rosa Iodice, Giuseppe Liberatore, Francesca Caleri, Anna Maria Repice, Susanna Cordera, Mario Alberto Battaglia, Marco Salvetti, Diego Franciotta, Antonio Uccelli. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021 Oct; 72(?):103581. doi: 10.1016/j.ebiom.2021.103581. [PMID: 34563483]
  • Fioravante Capone, Elisabetta Ferraro, Francesco Motolese, Vincenzo Di Lazzaro. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. Journal of neurology. 2021 Sep; 268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. [PMID: 33611610]
  • Redona Hafizi, Faik Imeri, Roland H Wenger, Andrea Huwiler. S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P1 and S1P3 Receptor Activation and HIF-2α Stabilization. International journal of molecular sciences. 2021 Aug; 22(17):. doi: 10.3390/ijms22179467. [PMID: 34502385]
  • Keizo Hiraishi, Lin Hai Kurahara, Jianlin Feng, Aya Yamamura, Yuanyuan Cui, Eiji Yahiro, Hiroyasu Yokomise, Tetsuhiko Go, Kaori Ishikawa, Naoya Yokota, Atsushi Fujiwara, Miki Onitsuka, Kohtaro Abe, Shoji Ohga, Toru Satoh, Yasumasa Okada, Lixia Yue, Ryuji Inoue, Katsuya Hirano. Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on pulmonary hypertension. Translational research : the journal of laboratory and clinical medicine. 2021 07; 233(?):127-143. doi: 10.1016/j.trsl.2021.03.004. [PMID: 33691194]
  • S Sen, R Karabudak, I Schiavetti, S Demir, S Ozakbas, M Tutuncu, B Petek Balci, O F Turan, C Uzunkopru, M Koseoglu, M F Yetkin, T Gunduz, H Gumus, N Kale Icen, L Carmisciano, M Terzi, P Acar, I Gungor Dogan, C Baba, A Tuncer, U Uygunoglu, M P Sormani, H Efendi, A Siva. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?. Multiple sclerosis and related disorders. 2021 Jul; 52(?):102968. doi: 10.1016/j.msard.2021.102968. [PMID: 33940495]
  • Ying Liu, Chun-Lin Yang, Bing Yang, Tong Du, Xiao-Li Li, Peng Zhang, Meng-Ru Ge, Ying Lian, Heng Li, Yu-Dong Liu, Rui-Sheng Duan. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells. International immunopharmacology. 2021 Jul; 96(?):107511. doi: 10.1016/j.intimp.2021.107511. [PMID: 33915521]
  • Mohammed Al Jumah, Ahmad Abulaban, Hani Aggad, Reem Al Bunyan, Mona AlKhawajah, Yaser Al Malik, Mousa Almejally, Hind Alnajashi, Foziah Alshamrani, Saeed Bohlega, Edward J Cupler, Ahmed ElBoghdady, Seraj Makkawi, Shireen Qureshi, Sahar Shami. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Multiple sclerosis and related disorders. 2021 Jun; 51(?):102925. doi: 10.1016/j.msard.2021.102925. [PMID: 33857897]
  • Hesham Salem, Fatma A Abo Elsoud, Dina Heshmat. Spectrofluorimetric analysis of fingolimod via complex formation with eosin Y in its pure form, pharmaceutical preparation and biological samples. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2021 Apr; 250(?):119331. doi: 10.1016/j.saa.2020.119331. [PMID: 33406450]
  • Gabriela Almeida Pimentel, Artur Martins Coutinho, Luis Filipe de Souza Godoy, Luiz Guilherme Cernaglia A de Lima, Daniel Ciampi de Andrade. Intense Hypermetabolic Tumefactive Demyelination on 18F-FDG PET and MRI Related to Multiple Sclerosis Relapse After Fingolimod Suspension. Clinical nuclear medicine. 2021 Apr; 46(4):e198-e199. doi: 10.1097/rlu.0000000000003419. [PMID: 33323727]
  • Giulia Mallucci, Antonio Zito, Fausto Baldanti, Matteo Gastaldi, Beatrice Dal Fabbro, Diego Franciotta, Roberto Bergamaschi. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Multiple sclerosis and related disorders. 2021 Apr; 49(?):102754. doi: 10.1016/j.msard.2021.102754. [PMID: 33609958]
  • Maria P Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano, Paola Zaratin, Gioacchino Tedeschi, Giancarlo Comi, Mario A Battaglia, Francesco Patti, Marco Salvetti. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of neurology. 2021 04; 89(4):780-789. doi: 10.1002/ana.26028. [PMID: 33480077]
  • Bhakta Prasad Gaire, Ji Woong Choi. Sphingosine 1-Phosphate Receptors in Cerebral Ischemia. Neuromolecular medicine. 2021 03; 23(1):211-223. doi: 10.1007/s12017-020-08614-2. [PMID: 32914259]
  • Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung, Alfred W Sandrock, Karen Smirnakis, Catrinel Popescu, Carl de Moor. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS drugs. 2021 03; 35(3):317-330. doi: 10.1007/s40263-021-00804-1. [PMID: 33743151]
  • Jerold Chun, Gavin Giovannoni, Samuel F Hunter. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs. 2021 Feb; 81(2):207-231. doi: 10.1007/s40265-020-01431-8. [PMID: 33289881]
  • Shumpei Azami, Fumie Konoeda, Hideki Sato. [A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod]. Rinsho shinkeigaku = Clinical neurology. 2021 Jan; 61(1):43-46. doi: 10.5692/clinicalneurol.cn-001412. [PMID: 33328415]
  • Pierre Ekobena, Anton Ivanyuk, Françoise Livio. [Pharmacovigilance update]. Revue medicale suisse. 2021 Jan; 17(720-1):80-84. doi: NULL. [PMID: 33443836]
  • Yvonne Naegelin, Jens Kuhle, Sabine Schädelin, Alexandre N Datta, Stefano Magon, Michael Amann, Christian Barro, Gian Paolo Ramelli, Kate Heesom, Yves-Alain Barde, Peter Weber, Ludwig Kappos. Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet journal of rare diseases. 2021 01; 16(1):19. doi: 10.1186/s13023-020-01655-7. [PMID: 33407685]
  • Deborah R Tasat, Juan S Yakisich. Rationale for the use of sphingosine analogues in COVID-19 patients. Clinical medicine (London, England). 2021 Jan; 21(1):e84-e87. doi: 10.7861/clinmed.2020-0309. [PMID: 33144402]
  • Ide Smets, Teresa Prezzemolo, Maya Imbrechts, Klara Mallants, Tania Mitera, Stéphanie Humblet-Baron, Bénédicte Dubois, Patrick Matthys, Adrian Liston, An Goris. Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis. Frontiers in immunology. 2021; 12(?):676619. doi: 10.3389/fimmu.2021.676619. [PMID: 34122439]
  • Victor Gomez-Mayordomo, Paloma Montero-Escribano, Jordi A Matías-Guiu, Nuria González-García, Jesús Porta-Etessam, Jorge Matías-Guiu. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. Journal of medical virology. 2021 01; 93(1):546-549. doi: 10.1002/jmv.26279. [PMID: 32644205]
  • Ran Luo, Yichun Cheng, Dan Chang, Tingting Liu, Liu Liu, Guangchang Pei, Nanhui Zhang, Zufeng Wang, Kanglin Guo, Wei Chen, Ming Li, Li Fan, Chunxiu Zhang, Yueqiang Li, Wei Dai, Meiying Zuo, Yulin Xu, Ying Yao, Shuwang Ge, Gang Xu. Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A. Theranostics. 2021; 11(1):117-131. doi: 10.7150/thno.48624. [PMID: 33391465]
  • Pece Kocovski, Nuzhat Tabassum-Sheikh, Stephanie Marinis, Phuc T Dang, Matthew W Hale, Jacqueline M Orian. Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior. Frontiers in immunology. 2021; 12(?):639650. doi: 10.3389/fimmu.2021.639650. [PMID: 34177891]
  • Ilkka Rauma, Heini Huhtala, Merja Soilu-Hänninen, Hanna Kuusisto. Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2020 12; 15(4):567-569. doi: 10.1007/s11481-020-09937-4. [PMID: 32729054]
  • David R Adams, Susan Pyne, Nigel J Pyne. Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases. Cellular signalling. 2020 12; 76(?):109806. doi: 10.1016/j.cellsig.2020.109806. [PMID: 33035646]
  • Yuan Zhong, Fei Tian, Huanxin Ma, Huihan Wang, Wei Yang, Zhuogang Liu, Aijun Liao. FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells. Life sciences. 2020 Nov; 260(?):118077. doi: 10.1016/j.lfs.2020.118077. [PMID: 32810509]
  • Malgorzata Kloc, Rafik M Ghobrial. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients. Multiple sclerosis and related disorders. 2020 Oct; 45(?):102437. doi: 10.1016/j.msard.2020.102437. [PMID: 32763844]
  • Sara Salama, Samar Farouk Ahmed, Ismail Ibrahim Ismail, Raed Alroughani. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clinical neurology and neurosurgery. 2020 10; 197(?):106203. doi: 10.1016/j.clineuro.2020.106203. [PMID: 32919242]
  • Giulia Mallucci, Antonio Zito, Beatrice Dal Fabbro, Roberto Bergamaschi. Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod. Multiple sclerosis and related disorders. 2020 10; 45(?):102414. doi: 10.1016/j.msard.2020.102414. [PMID: 32711296]
  • Luca Bollo, Tommaso Guerra, Davide Fiore Bavaro, Laura Monno, Annalisa Saracino, Gioacchino Angarano, Damiano Paolicelli, Maria Trojano, Pietro Iaffaldano. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. Journal of the neurological sciences. 2020 09; 416(?):117011. doi: 10.1016/j.jns.2020.117011. [PMID: 32650143]
  • James D Bowen, Justine Brink, Ted R Brown, Elisabeth B Lucassen, Kyle Smoot, Annette Wundes, Pavle Repovic. COVID-19 in MS: Initial observations from the Pacific Northwest. Neurology(R) neuroimmunology & neuroinflammation. 2020 09; 7(5):. doi: 10.1212/nxi.0000000000000783. [PMID: 32457226]
  • Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, Jens Pahnke. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis. Drugs in R&D. 2020 Sep; 20(3):197-207. doi: 10.1007/s40268-020-00316-1. [PMID: 32696271]
  • Paolo Preziosa, Maria A Rocca, Massimo Filippi. COVID-19 will change MS care forever - No. Multiple sclerosis (Houndmills, Basingstoke, England). 2020 09; 26(10):1149-1151. doi: 10.1177/1352458520929971. [PMID: 32567471]
  • Marco Chiarini, Simone Paghera, Daniele Moratto, Nicola De Rossi, Mauro Giacomelli, Raffaele Badolato, Ruggero Capra, Luisa Imberti. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection. Journal of neuroimmunology. 2020 08; 345(?):577282. doi: 10.1016/j.jneuroim.2020.577282. [PMID: 32505908]
  • Farinaz Safavi, Bardia Nourbakhsh, Amir Reza Azimi. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Multiple sclerosis and related disorders. 2020 Aug; 43(?):102195. doi: 10.1016/j.msard.2020.102195. [PMID: 32460086]
  • Carlos Guevara, Eduardo Villa, Carlos Silva Rosas, Violeta Diaz, Rodrigo Naves. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. Multiple sclerosis and related disorders. 2020 08; 43(?):102224. doi: 10.1016/j.msard.2020.102224. [PMID: 32464582]
  • David Baker, Sandra Amor, Angray S Kang, Klaus Schmierer, Gavin Giovannoni. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple sclerosis and related disorders. 2020 Aug; 43(?):102174. doi: 10.1016/j.msard.2020.102174. [PMID: 32464584]
  • Zhiliang Xie, Min Chen, Swagata Goswami, Rajes Mani, Dasheng Wang, Samuel K Kulp, Chris C Coss, Larry J Schaaf, Fengyu Cui, John C Byrd, Ryan N Jennings, Karsten K Schober, Carrie Freed, Stephanie Lewis, Raphael Malbrue, Natarajan Muthusamy, Chad Bennett, William C Kisseberth, Mitch A Phelps. Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. The AAPS journal. 2020 07; 22(4):92. doi: 10.1208/s12248-020-00474-9. [PMID: 32676788]
  • Mahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, Reza Sarrafi, Farzin Khorvash, Amir-Hadi Maghzi, Vahid Shaygannejad. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurology(R) neuroimmunology & neuroinflammation. 2020 07; 7(4):. doi: 10.1212/nxi.0000000000000753. [PMID: 32371550]
  • Noelyn Anne Hung, Fernando Guillermo Costa, Cheung-Tak Hung, Mónica Esther Rosenberg. Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design). Clinical pharmacology in drug development. 2020 07; 9(5):610-620. doi: 10.1002/cpdd.813. [PMID: 32468719]
  • Cristina Valencia-Sanchez, Dean M Wingerchuk. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Multiple sclerosis and related disorders. 2020 Jul; 42(?):102182. doi: 10.1016/j.msard.2020.102182. [PMID: 32416330]
  • Christian Foerch, Lucie Friedauer, Boris Bauer, Timo Wolf, Elisabeth H Adam. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Multiple sclerosis and related disorders. 2020 Jul; 42(?):102180. doi: 10.1016/j.msard.2020.102180. [PMID: 32408155]
  • Luo-Yi Wang, Xiao-Jing Sun, Chen Wang, Su-Fang Chen, Zhi-Ying Li, Min Chen, Mark A Little, Ming-Hui Zhao. Sphingosine-1-phosphate receptor modulator FTY720 attenuates experimental myeloperoxidase-ANCA vasculitis in a T cell-dependent manner. Clinical science (London, England : 1979). 2020 06; 134(12):1475-1489. doi: 10.1042/cs20200497. [PMID: 32538435]
  • Qianjin Li, Sudhirkumar Shinde, Giuliana Grasso, Antonio Caroli, Rahma Abouhany, Michele Lanzillotta, Guoqing Pan, Wei Wan, Knut Rurack, Börje Sellergren. Selective detection of phospholipids using molecularly imprinted fluorescent sensory core-shell particles. Scientific reports. 2020 06; 10(1):9924. doi: 10.1038/s41598-020-66802-3. [PMID: 32555511]
  • Henryk Jęśko, Przemysław L Wencel, Sylwia Wójtowicz, Joanna Strosznajder, Walter J Lukiw, Robert P Strosznajder. Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease. Molecular neurobiology. 2020 Jun; 57(6):2799-2811. doi: 10.1007/s12035-020-01908-3. [PMID: 32356173]
  • C Louapre, E Maillart, T Roux, V Pourcher, G Bussone, C Lubetzki, C Papeix. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum. Revue neurologique. 2020 06; 176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. [PMID: 32362357]
  • Longjun Li, Haitao Wang, Jun Zhang, Yeqin Sha, Fengjiao Wu, Shuang Wen, Lianping He, Liang Sheng, Qiang You, Meiqing Shi, Lixin Liu, Hong Zhou. SPHK1 deficiency protects mice from acetaminophen-induced ER stress and mitochondrial permeability transition. Cell death and differentiation. 2020 06; 27(6):1924-1937. doi: 10.1038/s41418-019-0471-x. [PMID: 31827236]
  • M D Willis, N P Robertson. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. Journal of neurology. 2020 05; 267(5):1567-1569. doi: 10.1007/s00415-020-09822-3. [PMID: 32303837]
  • Collin Tran, Benjamin Heng, Jonathan D Teo, Sean J Humphrey, Yanfei Qi, Timothy A Couttas, Holly Stefen, Merryn Brettle, Thomas Fath, Gilles J Guillemin, Anthony S Don. Sphingosine 1-phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes. Journal of neurochemistry. 2020 04; 153(2):173-188. doi: 10.1111/jnc.14917. [PMID: 31742704]
  • M Martinot, A Abou-Bacar, M Lamothe, M Alt Tebacher, M Mohseni Zadeh, F Dalle, L Favennec, D Costa, J Brunet, F Sellal. Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review. BMC infectious diseases. 2020 Mar; 20(1):257. doi: 10.1186/s12879-020-04988-7. [PMID: 32228484]
  • Sarah Matko, Katja Akgün, Torsten Tonn, Tjalf Ziemssen, Marcus Odendahl. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients. Multiple sclerosis and related disorders. 2020 Feb; 38(?):101859. doi: 10.1016/j.msard.2019.101859. [PMID: 31855843]
  • Chuqing Cao, Shuting Yang, Zhiguang Zhou. The potential application of Cordyceps in metabolic-related disorders. Phytotherapy research : PTR. 2020 Feb; 34(2):295-305. doi: 10.1002/ptr.6536. [PMID: 31667949]
  • Saeideh Ebrahimkhani, Heidi N Beadnall, Chenyu Wang, Catherine M Suter, Michael H Barnett, Michael E Buckland, Fatemeh Vafaee. Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment. Molecular neurobiology. 2020 Feb; 57(2):1245-1258. doi: 10.1007/s12035-019-01792-6. [PMID: 31721043]
  • Thomas V Rousselle, Canan Kuscu, Cem Kuscu, Kailo Schlegel, LiPing Huang, Maria Namwanje, James D Eason, Liza Makowski, Daniel Maluf, Valeria Mas, Amandeep Bajwa. FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury. Frontiers in immunology. 2020; 11(?):1278. doi: 10.3389/fimmu.2020.01278. [PMID: 32670281]
  • Xin Li, Ming Wu, Limin Chen, Junyan Lu, Guo Li, Lili Fu, Na Qi, Ye Lin, Zhongya Sun, Xueqi Wang, Hao Zhang, Jingqiu Liu, Hualiang Jiang, Lin Li, Chang-Lin Mei, Cheng Luo. A Sphingosine-1-Phosphate Modulator Ameliorates Polycystic Kidney Disease in Han:SPRD Rats. American journal of nephrology. 2020; 51(1):1-10. doi: 10.1159/000502855. [PMID: 31694015]
  • Katherine Stockstill, Carrie Wahlman, Kathryn Braden, Zhoumou Chen, Gina L Yosten, Dilip K Tosh, Kenneth A Jacobson, Timothy M Doyle, Willis K Samson, Daniela Salvemini. Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents. Pain. 2020 01; 161(1):177-184. doi: 10.1097/j.pain.0000000000001697. [PMID: 31490328]
  • Masayo Aoki, Akatsuki Kondo, Noriko Matsunaga, Azusa Honda, Yuri Okubo, Kazuaki Takabe, Rei Ogawa. The Immunosuppressant Fingolimod (FTY720) for the Treatment of Mechanical Force-Induced Abnormal Scars. Journal of immunology research. 2020; 2020(?):7057195. doi: 10.1155/2020/7057195. [PMID: 32377536]
  • Olga A Sukocheva, Elena Lukina, Eileen McGowan, Anupam Bishayee. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. Advances in protein chemistry and structural biology. 2020; 120(?):123-158. doi: 10.1016/bs.apcsb.2019.11.003. [PMID: 32085881]
  • Marwa A Abdel-Dayem, Mohamed E Shaker, Nariman M Gameil. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis. Journal of neuroimmunology. 2019 12; 337(?):577062. doi: 10.1016/j.jneuroim.2019.577062. [PMID: 31521828]
  • Murat Kürtüncü, Vuslat Yılmaz, Halil İbrahim Akçay, Recai Türkoğlu, Burcu Altunrende, Suzan Adın Çınar, Canan Ulusoy, Tuncay Gündüz, Sema İçöz, Mithat Kasap, Zeynep Çalışkan, Göktürk Ötünç, Mefküre Eraksoy, Erdem Tüzün. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. Journal of neuroimmunology. 2019 12; 337(?):577065. doi: 10.1016/j.jneuroim.2019.577065. [PMID: 31526917]
  • Victoria Gorbacheva, Ran Fan, Ashley Beavers, Robert L Fairchild, William M Baldwin, Anna Valujskikh. Anti-donor MHC Class II Alloantibody Induces Glomerular Injury in Mouse Renal Allografts Subjected to Prolonged Cold Ischemia. Journal of the American Society of Nephrology : JASN. 2019 12; 30(12):2413-2425. doi: 10.1681/asn.2018111169. [PMID: 31597715]
  • Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, Christian Thomas, Jonas Schmidt-Chanasit, Catharina C Gross, Andreas Schulte-Mecklenbeck, Heinz Wiendl, Sven G Meuth, Oliver M Grauer, Tobias Ruck. Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. International journal of molecular sciences. 2019 Nov; 20(23):. doi: 10.3390/ijms20235985. [PMID: 31795084]